Saturday 17 October 2026 Export CLDX’s income statement to Excel — free account

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024. In the quarter to June 2026, revenue fell 96.8%, EPS fell 10.6% and free cash flow fell 35.5%, each against the same quarter a year earlier.

27.53 1.40 −4.84%

Follow CLDX

Alert me

Market cap: $2.3B
P/E: 0.0×
Fwd P/E: −6.6×
Dividend yield: —
F-score: 2/9
Altman Z: 14.41
Beneish M: 6.76
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.30

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 2.47%

Capital & Financial Ratios $m

Market Cap 2,270.00

Revenue 0.89

Net Income (300.55)

Free Cash Flow (242.10)

Net Debt (716.36)

Current Ratio 11.82

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (6.61)

P/S ratio 2,415.94

P/B ratio 3.00

Past 5Y EPS Growth —

This Y EPS Growth (5.97%)

Next Y EPS Growth (2.07%)

Next Y revenue growth 19.74%

Next 5Y EPS Growth 4.66%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 97.20%

10-year low 10-year high

P/B against its own 10 years 60.67%

10-year low 10-year high

EV/Sales against its own 10 years 95.92%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	424	725	519	718
Receivables	3	1	2	0
Inventory	—	—	—	—
Other	—	—	—	—
	432	747	535	725

	2023	2024	2025	Q'26
Payables	3	3	1	15
ST’ Debt	4	1	1	1
Other	—	—	—	—
	31	40	51	61

Compound Annual Growth %

	10y	5y	3y
Sales	(11.89%)	(26.93%)	(13.13%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	6.15%	20.29%	17.35%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	1	1	—	0	2
’24	0	2	3	1	7
’23	1	0	2	4	7
’22	0	0	0	2	2
’21	1	3	0	0	5
’20	3	0	1	4	7

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(66)	(57)	—	—	—
’25	(54)	(44)	(49)	(64)	(211)
’24	(41)	(29)	(55)	(32)	(158)
’23	(29)	(27)	(19)	(33)	(107)
’22	(25)	(22)	(35)	(22)	(104)
’21	(18)	(12)	(16)	(15)	(61)
’20	(12)	(11)	(12)	(5)	(40)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(67)	(61)	—	—	—
’25	(55)	(45)	(49)	(65)	(214)
’24	(41)	(30)	(56)	(33)	(160)
’23	(29)	(28)	(19)	(33)	(109)
’22	(25)	(23)	(35)	(22)	(105)
’21	(19)	(12)	(17)	(15)	(62)
’20	(12)	(12)	(12)	(5)	(42)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.18)	(0.94)	—	—	—
’25	(0.81)	(0.85)	(1.01)	(1.22)	(3.90)
’24	(0.56)	(0.54)	(0.64)	(0.71)	(2.45)
’23	(0.62)	(0.65)	(0.81)	(0.83)	(2.92)
’22	(0.49)	(0.77)	(0.57)	(0.56)	(2.40)
’21	(0.42)	(0.34)	(0.45)	(0.43)	(1.64)
’20	(0.73)	(0.50)	(0.36)	(0.55)	(2.02)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	42.75	33.00	2.70	2.01	1.50	15.37	19.85	22.11	22.93	14.40	Analyst estimates 2026–2028 Powerpack
	High	234.15	60.30	46.20	11.55	23.40	57.20	46.04	48.40	53.18	30.50
People
People	Employees	210	197	137	130	125	134	148	160	186	198
	Revenue/emp, $m	0.03	0.06	0.07	0.03	0.06	0.03	0.02	0.04	0.04	0.01
Income, $m
Income, $m	Revenue	7	13	10	4	7	5	2	7	7	2
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(129)	(117)	(152)	(51)	(61)	(71)	(112)	(141)	(158)	(259)
	EBT margin, %	(1,894.05)	(920.61)	(1,593.09)	(1,423.96)	(821.61)	(1,520.92)	(4,765.59)	(2,054.76)	(2,248.76)	(16,748.03)
	Net income	(129)	(93)	(151)	(51)	(60)	(71)	(112)	(141)	(158)	(259)
	Depreciation	5	5	94	4	21	3	4	(3)	(13)	(2)
Per share, $
Per share, $	Revenue	1.00	1.49	0.91	0.25	0.25	0.11	0.05	0.14	0.11	0.02
	Earnings	(19.04)	(10.79)	(14.48)	(3.51)	(2.02)	(1.64)	(2.40)	(2.92)	(2.45)	(3.90)
	Cash flow	(16.70)	(11.66)	(7.20)	(3.20)	(1.36)	(1.42)	(2.21)	(2.21)	(2.45)	(3.18)
	Capex	(0.41)	(0.21)	(0.05)	(0.05)	(0.05)	(0.03)	(0.04)	(0.04)	(0.03)	(0.04)
	Free cash flow	(17.11)	(11.87)	(7.25)	(3.25)	(1.41)	(1.45)	(2.25)	(2.25)	(2.48)	(3.22)
	Book value	39.21	27.58	11.88	6.48	7.06	9.78	6.96	8.86	11.60	7.94
	Shares, m	7	9	10	15	30	43	47	48	64	66
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	54.01	29.46	3.28	9.05	70.00	356.16	863.16	284.44	231.80	663.24
	P/B	1.38	1.59	0.25	0.34	2.48	3.95	6.24	4.56	2.18	3.42
	EV/Sales	26.76	19.03	(6.10)	(7.94)	44.26	269.04	734.75	223.67	128.81	473.52
	EV/FCF	(1.57)	(2.38)	0.77	0.60	(7.84)	(20.14)	(16.42)	(14.11)	(5.66)	(6.03)
Cash, $m
Cash, $m	Operating cash flow	(113)	(100)	(75)	(46)	(40)	(61)	(104)	(107)	(158)	(211)
	Capex	(3)	(2)	0	(1)	(1)	(1)	(2)	(2)	(2)	(3)
	Free cash flow	(116)	(102)	(76)	(47)	(42)	(62)	(105)	(109)	(160)	(214)
Balance, $m
Balance, $m	Working capital	160	117	86	55	184	394	299	401	708	484
	Total debt	5	7	5	4	3	3	1	4	1	1
	Net debt	(185)	(133)	(89)	(61)	(191)	(405)	(304)	(420)	(724)	(517)
	Shareholders’ equity	265	236	124	94	209	419	326	429	747	527
Returns, %
Returns, %	ROA	(35.66)	(26.62)	(64.14)	(36.51)	(33.32)	(20.72)	(28.17)	(34.56)	(25.10)	(37.63)
	ROIC	(103.22)	(73.38)	(282.87)	(103.29)	(215.01)	(312.08)	(317.32)	(1,010.24)	(537.91)	(1,828.59)
	ROE	(46.27)	(37.08)	(83.89)	(46.66)	(39.41)	(22.43)	(30.13)	(37.45)	(26.84)	(40.62)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADMA ADMA Biologics Inc	$2.4B	14.8×	9.5×	+1.98% (above 0%: growing)	+21.43% (above 0%: growing)	+19.72% (above 0%: growing)	69.36%	42.16%	Compare
SLS SELLAS Life Sciences Group, Inc.	$2.3B	— (loss-making)	— (loss-making)	−57.10% (below 0%: shrinking)	n/m	−3.52% (below 0%: shrinking)	0.00%	0.00%	Compare
CLDX Celldex Therapeutics, Inc.	$2.3B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−35.45% (below 0%: shrinking)	100.00%	(366,468.18%)
AUPH Aurinia Pharmaceuticals Inc	$2.2B	6.9×	16.5×	+18.87% (above 0%: growing)	+81.25% (above 0%: growing)	+19.08% (above 0%: growing)	92.12%	48.19%	Compare
HRMY Harmony Biosciences Holdings, Inc.	$2.2B	12.2×	9.4×	+30.32% (above 0%: growing)	+88.41% (above 0%: growing)	+16.53% (above 0%: growing)	75.81%	34.18%	Compare
RXRX Recursion Pharmaceuticals, Inc.	$2.2B	— (loss-making)	— (loss-making)	−60.10% (below 0%: shrinking)	n/m	−32.03% (below 0%: shrinking)	(49.82%)	(1,759.69%)	Compare
VRDN Viridian Therapeutics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+278.67% (above 0%: growing)	n/m	−41.39% (below 0%: shrinking)	100.00%	(44,460.56%)	Compare
IRON Disc Medicine, Inc.	$2.2B	— (loss-making)	—	—	n/m	+7.83% (above 0%: growing)	0.00%	0.00%	Compare
FTRE Fortrea Holdings Inc.	$2.2B	— (loss-making)	— (loss-making)	−4.52% (below 0%: shrinking)	n/m	+53.15% (above 0%: growing)	20.52%	2.18%	Compare
Median of peers	$2.2B	12.2×	9.5×	+1.98%	+81.25%	+12.18%	44.94%	1.09%

All 614 Biotechnology stocks →

Celldex Therapeutics, Inc. (CLDX) key facts

Concern: Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
Concern: Celldex Therapeutics, Inc. reported a net loss of $258.8 million, or a loss of $3.90 per share, for fiscal 2025.
Celldex Therapeutics, Inc. (CLDX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CLDX traded at $27.53, a market capitalization of $2.3 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2,416× sales.
Return on equity was −40.6% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 14.41 (safe zone) for fiscal 2025.